Related references
Note: Only part of the references are listed.Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors
Christoph U. Correll et al.
WORLD PSYCHIATRY (2022)
Antipsychotic-induced weight gain: Is the weight over? New guidelines needed
Nini de Boer et al.
ACTA PSYCHIATRICA SCANDINAVICA (2022)
A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia
C. U. Correll et al.
CNS DRUGS (2022)
Criterion Validity of Linear Accelerations Measured with Low-Sampling-Frequency Accelerometers during Overground Walking in Elderly Patients with Knee Osteoarthritis
Arash Ghaffari et al.
SENSORS (2022)
A systematic review of licensed weight-loss medications in treating antipsychotic-induced weight gain and obesity in schizophrenia and psychosis
Kenn Lee et al.
GENERAL HOSPITAL PSYCHIATRY (2022)
Continuing, reducing, switching, or stopping antipsychotics in individuals with schizophrenia-spectrum disorders who are clinically stable: a systematic review and network meta-analysis
Giovanni Ostuzzi et al.
LANCET PSYCHIATRY (2022)
The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: Results of a pilot randomized, double-blind, placebo-controlled trial
Clare A. Whicher et al.
DIABETES OBESITY & METABOLISM (2021)
Liraglutide does not change bone turnover in clozapine- and olanzapine-treated schizophrenia overweight patients with prediabetes - randomized controlled trial
Henrik Maagensen et al.
PSYCHIATRY RESEARCH (2021)
Does Switching Antipsychotics Ameliorate Weight Gain in Patients With Severe Mental Illness? A Systematic Review and Meta-analysis
Dan Siskind et al.
SCHIZOPHRENIA BULLETIN (2021)
Effect of liraglutide 3.0mg treatment on weight reduction in obese antipsychotic-treated patients
Seung Eun Lee et al.
PSYCHIATRY RESEARCH (2021)
Efficacy and tolerability of pharmacological interventions on metabolic disturbance induced by atypical antipsychotics in adults: A systematic review and network meta-analysis
Yewei Wang et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2021)
20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20)
Heidi Taipale et al.
WORLD PSYCHIATRY (2020)
Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis
Dan Siskind et al.
DIABETES OBESITY & METABOLISM (2019)
Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis
Maximilian Huhn et al.
LANCET (2019)
Association With Hospitalization and All-Cause Discontinuation Among Patients With Schizophrenia on Clozapine vs Other Oral Second-Generation Antipsychotics A Systematic Review and Meta-analysis of Cohort Studies
Takahiro Masuda et al.
JAMA PSYCHIATRY (2019)
A comprehensive analysis of mortality-related health metrics associated with mental disorders: a nationwide, register-based cohort study
Oleguer Plana-Ripoll et al.
LANCET (2019)
High prevalence of prediabetes and metabolic abnormalities in overweight or obese schizophrenia patients treated with clozapine or olanzapine
Julie R. Larsen et al.
CNS SPECTRUMS (2019)
The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of meta-analyses of randomized controlled trials
Davy Vancampfort et al.
WORLD PSYCHIATRY (2019)
Clinical Guidance on the Identification and Management of Treatment-Resistant Schizophrenia
John M. Kane et al.
JOURNAL OF CLINICAL PSYCHIATRY (2019)
The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness
Joseph Firth et al.
LANCET PSYCHIATRY (2019)
What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?
Christoph U. Correll et al.
WORLD PSYCHIATRY (2018)
Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
Patrick M. O'Neil et al.
LANCET (2018)
Glucagon-like peptide-1 receptor agonists and fracture risk: a network meta-analysis of randomized clinical trials
Y. S. Zhang et al.
OSTEOPOROSIS INTERNATIONAL (2018)
Second-generation antipsychotic drugs and short-term mortality: a systematic review and meta-analysis of placebo-controlled randomised controlled trials
Johannes Schneider-Thoma et al.
LANCET PSYCHIATRY (2018)
Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial
Pelle L. Ishoy et al.
DIABETES OBESITY & METABOLISM (2017)
Orexin activation counteracts decreases in nonexercise activity thermogenesis (NEAT) caused by high-fat diet
P. E. Bunney et al.
PHYSIOLOGY & BEHAVIOR (2017)
Superwellness Program: a cognitive-behavioral therapy-based group intervention to reduce weight gain in patients treated with antipsychotic drugs
Laura R. Magni et al.
REVISTA BRASILEIRA DE PSIQUIATRIA (2017)
Sedentary behavior and physical activity levels in people with schizophrenia, bipolar disorder and major depressive disorder: a global systematic review and meta-analysis
Davy Vancampfort et al.
WORLD PSYCHIATRY (2017)
Assessment of Insulin Resistance Among Drug-Naive Patients With First-Episode Schizophrenia in the Context of Hormonal Stress Axis Activation
Johann Steiner et al.
JAMA PSYCHIATRY (2017)
Impaired Glucose Homeostasis in First-Episode Schizophrenia A Systematic Review and Meta-analysis
Toby Pillinger et al.
JAMA PSYCHIATRY (2017)
Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder A Randomized Clinical Trial
Julie R. Larsen et al.
JAMA PSYCHIATRY (2017)
Mortality gap for people with bipolar disorder and schizophrenia: UK-based cohort study 2000-2014
Joseph F. Hayes et al.
BRITISH JOURNAL OF PSYCHIATRY (2017)
Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology
Oliver D. Howes et al.
AMERICAN JOURNAL OF PSYCHIATRY (2017)
PANSS-6: a brief rating scale for the measurement of severity in schizophrenia
S. D. Ostergaard et al.
ACTA PSYCHIATRICA SCANDINAVICA (2016)
Efficacy and safety of adjunctive topiramate for schizophrenia: a meta-analysis of randomized controlled trials
W. Zheng et al.
ACTA PSYCHIATRICA SCANDINAVICA (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The CHANGE trial: no superiority of lifestyle coaching plus care coordination plus treatment as usual compared to treatment as usual alone in reducing risk of cardiovascular disease in adults with schizophrenia spectrum disorders and abdominal obesity
Helene Speyer et al.
WORLD PSYCHIATRY (2016)
The association between first-episode psychosis and abnormal glycaemic control: systematic review and meta-analysis
Benjamin Ian Perry et al.
LANCET PSYCHIATRY (2016)
The STRIDE Weight Loss and Lifestyle Intervention for Individuals Taking Antipsychotic Medications: A Randomized Trial
Carla A. Green et al.
AMERICAN JOURNAL OF PSYCHIATRY (2015)
GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women
Eva W. Iepsen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Metformin for Weight Gain and Metabolic Abnormalities Associated With Antipsychotic Treatment Meta-Analysis of Randomized Placebo-Controlled Trials
Wei Zheng et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2015)
Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
Jesper Lau et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Efficacy of Adjunctive Treatments Added to Olanzapine or Clozapine for Weight Control in Patients with Schizophrenia: A Systematic Review and Meta-Analysis
Yun-Jung Choi
TheScientificWorldJOURNAL (2015)
Mortality in Mental Disorders and Global Disease Burden Implications A Systematic Review and Meta-analysis
Elizabeth Reisinger Walker et al.
JAMA PSYCHIATRY (2015)
Efficacy of Adjunctive Treatments Added to Olanzapine or Clozapine for Weight Control in Patients with Schizophrenia: A Systematic Review and Meta-Analysis
Yun-Jung Choi
Scientific World Journal (2015)
Schizophrenia
Rene S. Kahn et al.
NATURE REVIEWS DISEASE PRIMERS (2015)
Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses
David C. Henderson et al.
LANCET PSYCHIATRY (2015)
Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients
Chun-Jun Li et al.
CARDIOVASCULAR DIABETOLOGY (2014)
Pharmacological Strategies to Counteract Antipsychotic-Induced Weight Gain and Metabolic Adverse Effects in Schizophrenia: A Systematic Review and Meta-analysis
Yuya Mizuno et al.
SCHIZOPHRENIA BULLETIN (2014)
The Effectiveness of Lifestyle Interventions to Reduce Cardiovascular Risk in Patients with Severe Mental Disorders: Meta-Analysis of Intervention Studies
Maria Isabel Fernandez-San-Martin et al.
COMMUNITY MENTAL HEALTH JOURNAL (2014)
被撤回的出版物: World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects (Retracted article. See vol. 135, pg. 2149, 2021)
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Effect of Topiramate on Weight Gain in Patients Receiving Atypical Antipsychotic Agents
Shamail Mahmood et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2013)
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
An-Wen Chan et al.
BMJ-BRITISH MEDICAL JOURNAL (2013)
The gap in life expectancy from preventable physical illness in psychiatric patients in Western Australia: retrospective analysis of population based registers
David Lawrence et al.
BMJ-BRITISH MEDICAL JOURNAL (2013)
Gastric bypass surgery for obesity decreases the reward value of a sweet-fat stimulus as assessed in a progressive ratio task
Alexander D. Miras et al.
AMERICAN JOURNAL OF CLINICAL NUTRITION (2012)
Health promotion lifestyle interventions for weight management in psychosis: a systematic review and meta-analysis of randomised controlled trials
Elena Bonfioli et al.
BMC PSYCHIATRY (2012)
Life expectancy and cardiovascular mortality in persons with schizophrenia
Thomas M. Laursen et al.
CURRENT OPINION IN PSYCHIATRY (2012)
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs
Marc De Hert et al.
NATURE REVIEWS ENDOCRINOLOGY (2012)
Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: A meta-analytic comparison of randomized controlled trials
Jacqueline Caemmerer et al.
SCHIZOPHRENIA RESEARCH (2012)
Are there different neural mechanisms responsible for three stages of weight gain development in anti-psychotic therapy: Temporally based hypothesis
Nagesh Pai et al.
ASIAN JOURNAL OF PSYCHIATRY (2012)
Systematic Review and Meta-analysis of Pharmacological Interventions for Weight Gain from Antipsychotics and Mood Stabilizers
Jess G. Fiedorowicz et al.
CURRENT PSYCHIATRY REVIEWS (2012)
Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis
Samir Kumar Praharaj et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Physical health disparities and mental illness: the scandal of premature mortality
Graham Thornicroft
BRITISH JOURNAL OF PSYCHIATRY (2011)
Antipsychotic drugs and obesity
Christoph U. Correll et al.
TRENDS IN MOLECULAR MEDICINE (2011)
Radiation exposure in X-ray-based imaging techniques used in osteoporosis
John Damilakis et al.
EUROPEAN RADIOLOGY (2010)
The Effect of Metformin on Anthropometrics and Insulin Resistance in Patients Receiving Atypical Antipsychotic Agents: A Meta-Analysis
Megan Ehret et al.
JOURNAL OF CLINICAL PSYCHIATRY (2010)
Effectiveness of Medications Used to Attenuate Antipsychotic-Related Weight Gain and Metabolic Abnormalities: A Systematic Review and Meta-Analysis
Lawrence Maayan et al.
NEUROPSYCHOPHARMACOLOGY (2010)
Changes in weight and body mass index during treatment with melperone, clozapine and typical neuroleptics
William V. Bobo et al.
PSYCHIATRY RESEARCH (2010)
Quality of medical care for people with and without comorbid mental illness and substance misuse: systematic review of comparative studies
Alex J. Mitchell et al.
BRITISH JOURNAL OF PSYCHIATRY (2009)
Weight gain with clozapine: 8-year cohort naturalistic study among hospitalized Chinese schizophrenia patients
Ya-Mei Bai et al.
SCHIZOPHRENIA RESEARCH (2009)
A systematic review of mortality in schizophrenia - Is the differential mortality gap worsening over time?
Sukanta Saha et al.
ARCHIVES OF GENERAL PSYCHIATRY (2007)
The physiology of glucagon-like peptide 1
Jens Juul Holst
PHYSIOLOGICAL REVIEWS (2007)
Schizophrenia and increased risks of cardiovascular disease
CH Hennekens et al.
AMERICAN HEART JOURNAL (2005)
Evaluation of the Drug Use Disorders Identification Test (DUDIT) in criminal justice and detoxification settings and in a Swedish population sample
AH Berman et al.
EUROPEAN ADDICTION RESEARCH (2005)
Diet, smoking and cardiovascular risk in people with schizophrenia - Descriptive study
RG McCreadie
BRITISH JOURNAL OF PSYCHIATRY (2003)
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study
DC Henderson et al.
AMERICAN JOURNAL OF PSYCHIATRY (2000)
Share Paper
